


PRODUCT INFORMATION



Arachidonoyl-N,N-dimethyl amide

Item No. 10007293

CAS Registry No.: 45280-17-9
Formal Name: N,N-dimethyl-5Z,8Z,11Z,14Z-eicosatetraenamide
Synonym: Arachidonic Acid-N,N-dimethyl amide
MF: C₂₂H₃₇NO
FW: 331.5
Purity: ≥98%
Supplied as: A solution in methyl acetate
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Arachidonoyl-N,N-dimethyl amide is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of arachidonoyl-N,N-dimethyl amide in these solvents is approximately 10 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. For greater aqueous solubility, arachidonoyl-N,N-dimethyl amide can be prepared by evaporating the methyl acetate and directly dissolving in 0.1 M Na₂CO₃ (0.1 M) and then diluted with PBS (pH 7.2) to achieve the desired concentration or pH. We do not recommend storing the aqueous solution for more than one day.

Description

Anandamide (AEA) is an endogenous cannabinoid that binds to both central cannabinoid (CB₁) and peripheral cannabinoid (CB₂) receptors. The biological actions of AEA are terminated by cellular uptake and hydrolysis of the amide bond by the enzyme fatty acid amide hydrolase. Arachidonoyl-N,N-dimethyl amide is an analog of AEA that exhibits weak or no binding to the human CB₁ receptor (K_i >1 μM).¹ It inhibits rat glial gap junction cell-cell communication 100% at a concentration of 50 μM.²

References

1. Sheskin, T., Hanus, L., Slager, J., *et al.* Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. *J. Med. Chem.* **40**, 659-667 (1997).
2. Boger, D.L., Sato, H., Lerner, A.E., *et al.* Arachidonic acid amide inhibitors of gap junction cell-cell communication. *Bioorg. Medicinal Chem. Letters* **9**, 1151-1154 (1999).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/22/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM